

Brigham and Women's Hospital - EXHIBIT 2004
PreOmics GmbH and Biognosys AG v. The Brigham and Women's Hospital, Inc.
IPR2024-01473

Contact

www.linkedin.com/in/omidfarokhzad (LinkedIn)
www.seer.bio (Company)

Omid Farokhzad

Chair, CEO and Founder at Seer
San Francisco Bay Area

Summary

Omid Farokhzad is the Chair and Chief Executive Officer for Seer. He serves as Director of Senti Bio (NASDAQ: SNTI) and Chair of PrognomiQ. Previously, he was Professor at Harvard Medical School and directed the Center for Nanomedicine at Brigham and Women's Hospital. He has authored over 190 papers and is an inventor of over 200 issued and pending patents. Omid previously founded BIND Therapeutics (NASDAQ: BIND, acquired by Pfizer) and Selecta Biosciences (NASDAQ: SELB, merged with Cartesian Therapeutics); and and PrognomiQ. He is a 2018 Fellow of the National Academy of Inventors. He is a recipient of the 2016 Ellis Island Medal of Honor and the 2014 Golden Door Award from the International Institute of New England, for his scientific, societal and economic contributions to America as an immigrant; the 2023 Mustafa Prize and the 2013 RUSNANOPRIZE for his work on nanomaterial surface modification; and the 2012 Ernst & Young New England Entrepreneur of the Year award. He received his M.D. and M.A. from Boston University and his M.B.A. from MIT Sloan School of Management.

Experience

Seer

Chair, CEO and Founder

March 2018 - Present (6 years 10 months)

Chair (2020 -)

PrognomiQ Inc

Chair and Founder

September 2020 - Present (4 years 4 months)

San Francisco Bay Area

Harvard Medical School

Professor of Anesthesiology (2004 - 2020); Senior Lecturer (2020 - present)

2004 - Present (20 years)

Senti Biosciences

Director

June 2022 - November 2024 (2 years 6 months)

Audit Committee (2024 - 2024)

Dynamics Special Purpose Corp.

Executive Chair and Founder

May 2021 - June 2022 (1 year 2 months)

Selecta Biosciences

Director, Chairman (2008 - 2019) and Founder

2008 - 2022 (14 years)

NASDAQ: SELB

Chairman (2018 - 2019)

Director (2008 - 2018)

Science Committee (2018 - 2019)

Nomination and Governance Committee (2016 - 2017)

Vice Chairman (2008 - 2015)

Scientific Advisory Board (2008 - 2022)

Tarveda Therapeutics (Formerly Blend Therapeutics)

Director (2011 - 2019) and Founder

2011 - 2021 (10 years)

Chairman (2014 - 2015)

Scientific Advisory Board (2011 - 2021)

Brigham and Women's Hospital

Director, Center for Nanomedicine (2016 - 2020), Lab of Nanomedicine (2004 - 2020)

October 2004 - February 2018 (13 years 5 months)

BIND Therapeutics

Director (2006-2014) and Founder

2006 - 2015 (9 years)

NASDAQ: BIND; Acquired by Pfizer

Scientific Advisory Board (2006 - 2015)

Education

Harvard Medical School

Brigham and Women's Hospital, Residency in Anesthesiology and Fellowship in Pain Medicine

Massachusetts Institute of Technology

Harvard-MIT Division of Health Sciences and Technology, Post-doctoral Fellowship in Nanomedicine and Biomaterials

Massachusetts Institute of Technology - Sloan School of Management

M.B.A.

Boston University School of Medicine

M.D., M.A.